Dupixent Sanofi-Aventis Australia Pty Ltd
Product name
Dupixent
Sponsor
Accepted date
Nov-2025
Active ingredients
dupilumab
Proposed indication
DUPIXENT (dupilumab) is proposed for the treatment of adult patients with bullous pemphigoid, a chronic autoimmune skin condition that causes large, fluid-filled blisters.
Application type
C (new indication)
Publication date
Nov-2025
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.